Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Common Equity (2020 - 2025)

Sight Sciences has reported Common Equity over the past 6 years, most recently at $63.9 million for Q4 2025.

  • Quarterly results put Common Equity at $63.9 million for Q4 2025, down 26.94% from a year ago — trailing twelve months through Dec 2025 was $63.9 million (down 26.94% YoY), and the annual figure for FY2025 was $63.9 million, down 26.94%.
  • Common Equity for Q4 2025 was $63.9 million at Sight Sciences, down from $64.3 million in the prior quarter.
  • Over the last five years, Common Equity for SGHT hit a ceiling of $232.1 million in Q4 2021 and a floor of -$246.0 million in Q3 2021.
  • Median Common Equity over the past 5 years was $105.4 million (2024), compared with a mean of $85.2 million.
  • Peak annual rise in Common Equity hit 361.24% in 2021, while the deepest fall reached 207.62% in 2021.
  • Sight Sciences' Common Equity stood at $232.1 million in 2021, then plummeted by 31.03% to $160.1 million in 2022, then fell by 24.9% to $120.2 million in 2023, then fell by 27.19% to $87.5 million in 2024, then decreased by 26.94% to $63.9 million in 2025.
  • The last three reported values for Common Equity were $63.9 million (Q4 2025), $64.3 million (Q3 2025), and $70.0 million (Q2 2025) per Business Quant data.